Dapagliflozin, Saxagliptin, And Metformin Hydrochloride

Introduction Overview

Generic Name

dapagliflozin, saxagliptin, and metformin hydrochloride

Brand Name

Qternmet XR

Dosage Form

Extended-Release Tablets

Drug Class

SGLT2 inhibitor (dapagliflozin), DPP-4 inhibitor (saxagliptin), Biguanide (metformin hydrochloride)

Pharmacokinetics

Absorption: Qternmet XR combines dapagliflozin, saxagliptin, and metformin hydrochloride into once-daily extended-release tablets. Upon oral administration with food, dapagliflozin is rapidly absorbed reaching peak plasma concentrations within 1 to 2 hours, with an absolute bioavailability of approximately 78%. Saxagliptin is also well absorbed orally with peak plasma levels reached within 2 hours and high bioavailability (~75%). Metformin extended-release tablets have a slower absorption with peak plasma concentrations reached within 7 hours, providing sustained plasma levels to optimize glycemic control. Food intake tends to reduce peak plasma concentration (Cmax) but not the overall absorption (AUC) of metformin, which supports administration with meals to enhance gastrointestinal tolerability.

Distribution: Dapagliflozin displays a volume of distribution (Vd) of approximately 118 liters, indicating extensive tissue distribution, with about 91% plasma protein binding. Saxagliptin's apparent volume of distribution is roughly 151 liters, with about 50% protein binding, affecting tissue penetration and half-life. Metformin has a volume of distribution near 654 liters, reflecting significant distribution into erythrocytes and tissues, with negligible protein binding. These distribution characteristics imply that metformin extensively distributes beyond plasma, while dapagliflozin and saxagliptin show moderate tissue uptake.

Metabolism: Dapagliflozin undergoes primary hepatic metabolism mainly via UGT1A9-mediated glucuronidation to inactive metabolites, with minimal involvement of the cytochrome P450 system, leading to limited potential for CYP-mediated drug interactions. Saxagliptin is metabolized via CYP3A4/5 enzymes to an active metabolite, 5-hydroxy saxagliptin, which contributes to its DPP-4 inhibitory activity, prolonging its pharmacodynamic effects. Metformin is not metabolized hepatically and is excreted unchanged by the kidneys, reducing concerns of hepatic enzyme-mediated drug interactions but necessitating renal function monitoring.

Elimination: Dapagliflozin is eliminated primarily via urinary excretion of metabolites after hepatic metabolism, with an elimination half-life of approximately 12.9 hours, supporting once-daily dosing. Saxagliptin and its active metabolite are eliminated both renally and hepatically, with a half-life of about 2.5 hours for saxagliptin and roughly 4 hours for the active metabolite. Metformin is eliminated unchanged via renal excretion with a half-life around 6.5 hours; therefore, renal impairment significantly affects metformin clearance, increasing risk for accumulation and lactic acidosis. Dosage adjustments or discontinuation are advised in cases of moderate to severe renal impairment. Overall, the pharmacokinetics of the combination therapy necessitate consideration of hepatic and renal functions to optimize dosing and minimize adverse effects.

Dosage Forms

Available Dosage Forms: Qternmet XR is available as extended-release oral tablets formulated to deliver a combination of dapagliflozin, saxagliptin, and metformin hydrochloride. Typical fixed-dose combinations are designed to improve adherence by combining three agents with complementary mechanisms into a single daily tablet. Specifically, the tablets are extended-release to allow once-daily dosing with minimized peaks and troughs. The exact tablet strengths are commercially available in various dose combinations to tailor therapy according to individual patient needs, although the detailed specific mg per tablet were not explicitly listed in the provided data.

Dosages for Adults and Adolescents: Qternmet XR is approved for use in adults with type 2 diabetes mellitus inadequately controlled with metformin. It is specifically indicated for patients currently stabilized on metformin therapy. There is no established efficacy or safety data for pediatric use; hence, it is not recommended for children under 18 years of age. Initial dosing usually involves administration of one tablet once daily in the morning with food to reduce gastrointestinal adverse effects. Dose titration or adjustment is based on glycemic response and tolerability within the prescribing guidelines. Dose adjustments may also be necessary based on renal function or concomitant medications.

Specific Patient Populations: For patients with renal impairment, Qternmet XR is contraindicated in moderate to severe renal dysfunction or those on dialysis due to metformin accumulation risk and reduced efficacy of dapagliflozin. Hepatic impairment also warrants caution and possible discontinuation as it increases lactic acidosis risk and may impair metabolism of dapagliflozin and saxagliptin. Elderly patients (>65 years) require careful monitoring for dehydration and orthostatic hypotension. Dosage adjustments or discontinuation are necessary in settings of acute illness, surgery, or radiologic studies requiring contrast agents to reduce adverse events. Pregnancy and breastfeeding patients should avoid the drug due to potential fetal harm and unknown risks in human milk. Patient-specific factors such as heart failure, history of pancreatitis, or bladder cancer necessitate risk vs benefit assessment before initiation.

Mechanism Of Action

Qternmet XR combines three pharmacologically distinct agents, each targeting different pathophysiological aspects of type 2 diabetes mellitus to achieve improved glycemic control. The first component, dapagliflozin, is a selective inhibitor of sodium-glucose co-transporter 2 (SGLT2) located in the proximal renal tubules. By blocking SGLT2, dapagliflozin reduces glucose reabsorption from the glomerular filtrate back into the bloodstream, promoting urinary glucose excretion and thereby lowering plasma glucose levels independently of insulin secretion.

Saxagliptin, the second active ingredient, is a dipeptidyl peptidase-4 (DPP-4) inhibitor. DPP-4 is an enzyme responsible for degrading incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Inhibiting DPP-4 prolongs the half-life of endogenous incretins, enhancing glucose-dependent stimulation of insulin release from pancreatic beta cells and suppressing glucagon secretion from alpha cells. This leads to improved postprandial glucose regulation and contributes to overall glycemic control.

Metformin hydrochloride, the third constituent, is a biguanide that primarily functions by decreasing hepatic gluconeogenesis, thus reducing hepatic glucose output. Additionally, metformin improves peripheral insulin sensitivity, enhancing glucose uptake and utilization in skeletal muscle and adipose tissue. Unlike other antihyperglycemic agents, metformin does not stimulate insulin secretion directly, which reduces hypoglycemia risk.

The combination therapy in Qternmet XR leverages these complementary mechanisms: dapagliflozin facilitating glucose excretion, saxagliptin augmenting endogenous insulin secretion via incretin pathways, and metformin diminishing hepatic glucose production. This triple modality addresses multiple pathophysiologic defects inherent in type 2 diabetes mellitus, resulting in synergistic improvement in fasting and postprandial glucose levels. Additionally, the use of extended-release formulation optimizes the pharmacokinetic profiles of each component, allowing convenient once-daily dosing with sustained efficacy and enhanced patient adherence. Clinical studies have demonstrated that this combinational approach yields superior glycemic control compared to dual or monotherapies, with favorable tolerability profiles.

Pharmacological Actions

Inhibits renal glucose reabsorption via SGLT2 blockade, promoting glucosuria (dapagliflozin).
Enhances incretin hormone levels through DPP-4 inhibition, increasing insulin release and decreasing glucagon secretion (saxagliptin).
Suppresses hepatic gluconeogenesis and improves insulin sensitivity to reduce plasma glucose (metformin).
Lowers both fasting and postprandial blood glucose levels through complementary mechanisms.
Reduces glycemic variability improving overall blood sugar control.
Minimal risk of hypoglycemia as components act via glucose-dependent pathways or reduce glucose production.
Contributes to modest weight loss due to caloric loss in urine from glucosuria.
Lowers blood pressure modestly via osmotic diuresis induced by SGLT2 inhibition.
Improves beta-cell function and insulin secretion through incretin enhancement.
Exhibits cardio-renal protective benefits beyond glycemic control, particularly dapagliflozin component.
Extended-release formulation provides steady-state plasma concentrations facilitating once-daily dosing.
Reduces risk factors associated with type 2 diabetes complications including dyslipidemia.
Demonstrates synergy reducing required doses of individual agents thus limiting adverse effects.

Therapeutic Or Clinical Uses

Management of type 2 diabetes mellitus in adults to improve glycemic control.
Adjunct to diet and exercise for adults inadequately controlled on metformin monotherapy.
Alternative therapy for patients requiring multiple antihyperglycemic agents.
Treatment option for patients where weight neutrality or modest weight reduction is desirable.
Improvement of fasting and postprandial blood glucose levels simultaneously.
Potential cardiovascular risk reduction in patients with type 2 diabetes (dapagliflozin component).
Use in patients without significant renal impairment or contraindications to components.
Combination therapy to enhance patient adherence by minimizing pill burden.
Off-label consideration in patients intolerant to insulin or other injectable therapies.
Option for patients at risk of hypoglycemia due to glucose-dependent mechanism of action.
Management of dyslipidemia in conjunction with glycemic control.
Use in patients with stable hepatic function under medical supervision.
Address multiple pathophysiologic defects using a single fixed-dose combination.

Side Or Adverse Effects

Lactic acidosis, a rare but potentially fatal metabolic complication associated with metformin.
Pancreatitis, possible serious inflammation of the pancreas linked to saxagliptin use.
Heart failure or worsening heart failure in predisposed individuals.
Dehydration leading to dizziness, orthostatic hypotension, and electrolyte imbalances.
Risk of diabetic ketoacidosis despite normal or mildly elevated blood glucose levels.
Genitourinary infections including vaginal yeast infections and balanitis.
Serious urinary tract infections sometimes requiring hospitalization.
Necrotizing fasciitis of the perineum (Fournier’s gangrene), a rare but serious infection.
Hypoglycemia especially when combined with insulin or sulfonylureas.
Hypersensitivity reactions including angioedema, rash, itching, and hives.
Vitamin B12 deficiency with long-term metformin use leading to neuropathy risk.
Increase in low-density lipoprotein (LDL) cholesterol levels.
Bladder cancer occurrences reported with dapagliflozin in clinical studies.
Joint pain potentially severe associated with DPP-4 inhibitors.
Bullous pemphigoid, an autoimmune blistering skin condition linked to DPP-4 inhibition.

Precautions

Assess renal function prior to initiation and regularly during therapy; contraindicated in moderate to severe renal impairment.
Monitor for signs and symptoms of lactic acidosis especially in those with hepatic impairment or conditions predisposing to hypoxia.
Avoid use in patients with a history of diabetic ketoacidosis or type 1 diabetes mellitus.
Use caution in patients with a history of pancreatitis or gallstones.
Monitor for heart failure symptoms; discontinue if heart failure worsens.
Educate patients on recognizing signs of serious infections, especially genitourinary infections.
Advise patients to maintain hydration to minimize risk of volume depletion and kidney injury.
Use cautiously in elderly patients due to increased susceptibility to dehydration and orthostatic hypotension.
Avoid use in patients with bladder cancer, current or history of malignancy of the bladder.
Discontinue prior to procedures involving iodinated contrast to reduce renal injury risk.
Counsel women on potential increased fertility risk due to ovulation induction.
Advise against alcohol consumption to reduce risk of lactic acidosis and hypoglycemia.
Regularly monitor vitamin B12 levels in patients on long-term metformin therapy.
Evaluate risk versus benefit in patients with hepatic disease.
Use caution in patients on concomitant medications that may affect glycemic control or volume status.

Warnings

Boxed warning for lactic acidosis associated with metformin component; medical emergency requiring immediate attention.
Serious risk of pancreatitis linked with saxagliptin necessitating prompt discontinuation if suspected.
Potential worsening or new onset of heart failure; discontinue if signs appear.
Risk of ketoacidosis even with normal glucose levels requiring vigilance during illness or stress.
Serious urinary tract infections and necrotizing fasciitis of perineum have been reported.
Hypersensitivity reactions, including life-threatening angioedema, require immediate cessation.
Avoid use in patients with moderate to severe kidney impairment and those on dialysis.
Discontinuation recommended prior to major surgery or radiographic studies requiring contrast dye.
Avoid in type 1 diabetes or for treatment of diabetic ketoacidosis.
May cause symptomatic dehydration; monitor blood pressure and volume status closely.
Increased risk of bone fractures reported in chronic SGLT2 inhibitor use.
Potential increased risk for bladder cancer; monitor urinary symptoms promptly.
Use with caution in patients with history of alcohol abuse.
Do not use in patients allergic to any active or inactive ingredients.
Consult healthcare provider if unusual muscle pain, weakness, or respiratory symptoms develop.

Contraindication

Known hypersensitivity to dapagliflozin, saxagliptin, metformin hydrochloride, or any inactive ingredients.
Moderate to severe renal impairment or patients on dialysis (due to metformin accumulation risk).
Metabolic acidosis including diabetic ketoacidosis.
Type 1 diabetes mellitus.
Acute or chronic metabolic acidosis.
Severe hepatic impairment or conditions predisposing to lactic acidosis.
History of allergic reaction to DPP-4 inhibitors including angioedema.
Patients with bladder cancer or suspected bladder malignancy.
Concomitant use with other SGLT2 inhibitors or DPP-4 inhibitors.
Patients undergoing radiologic studies involving iodinated contrast agents unless temporarily discontinued.
Pregnancy (due to potential fetal harm).
Breastfeeding women due to unknown drug presence in milk and potential risks.
Acute illnesses predisposing to hypoxia or dehydration without proper medical management.
Patients with severe infections or hemodynamic instability.
Individuals with conditions causing dehydration or low blood pressure unless monitored closely.

Drug Interactions

Concomitant use with diuretics increases risk of volume depletion and hypotension.
CYP3A4/5 inhibitors or inducers may alter saxagliptin plasma concentrations.
Use with insulin or insulin secretagogues (e.g., sulfonylureas) increases hypoglycemia risk.
Concurrent use with nephrotoxic drugs may exacerbate renal impairment.
Drugs affecting gastrointestinal motility may alter absorption of metformin.
Co-administration with alcohol can potentiate risk of lactic acidosis.
Some antifungal agents and antiretrovirals may affect metabolic pathways of saxagliptin.
Concomitant use with other antihypertensives may potentiate hypotensive effects.
Use with iodinated contrast media may increase risk of acute renal failure.
Medications that alter electrolyte balance may compound dehydration risk.
Drugs that increase blood glucose could reduce efficacy of Qternmet XR components.
Agents inducing CYP enzymes may reduce saxagliptin efficacy.
Medications affecting vitamin B12 absorption (e.g., proton pump inhibitors) may worsen deficiency risk with metformin.
Caution with drugs causing QT prolongation due to possible additive effects (monitor closely).
Herbal supplements with hypoglycemic potential may increase risk of low blood sugar.

Preparations Of The Drug

Qternmet XR extended-release tablets combining fixed doses of dapagliflozin, saxagliptin, and metformin hydrochloride.
Tablets formulated with excipients such as carboxymethyl cellulose sodium, crospovidone, hypromellose 2208, iron oxides, lactose anhydrous, magnesium stearate, microcrystalline cellulose, polyvinyl alcohol, macrogol/polyethylene glycol, silicon dioxide, talc, and titanium dioxide.
Formulated for once-daily administration to optimize patient compliance.
Manufactured under sterile, controlled conditions by AstraZeneca with adherence to FDA regulations.
Packaged with patient information leaflets emphasizing warnings, dosing instructions, and storage recommendations.
Available in multiple strength variations to facilitate individual dose optimization.
Extended-release matrix to allow gradual drug release and steady plasma levels.
Co-formulated to maintain chemical and physical stability of all three active components.
Blister or bottle packaging to protect tablets from moisture, light, and contamination.
Contains lactose anhydrous, requiring caution in patients with lactose intolerance.
Stable at recommended storage conditions of 20°C to 25°C (68°F to 77°F).
Color-coded and imprinted tablets for easy identification.
Includes inactive ingredients that aid in tablet integrity, release, and patient acceptability.
Refrigeration not required, but should be kept out of reach of children and pets.
Distributed with professional prescribing information and updated safety data.